Masahiko Yano

Masahiko Yano

Auto-generated profile, based on publicly available information

Masahiko Yano

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Pancreatology
Verified
Journal Article
Closed access
HTHidenori Takahashi
Hidenori Takahashi
DYDaisaku Yamada
Daisaku Yamada
KAKei Asukai
Kei Asukai
HWHiroshi Wada
Hiroshi Wada
SHShinichiro Hasegawa
Shinichiro Hasegawa
OIOsamu Ishikawa
Osamu Ishikawa

29 May 2017 in Anticancer Research
Verified
Journal Article
Open access
PDF file
HMHiroshi Miyata
Hiroshi Miyata
KSKeijiro Sugimura
Keijiro Sugimura
MMMasaaki Motoori
Masaaki Motoori
YFYoshiyuki Fujiwara
Yoshiyuki Fujiwara
TOTakeshi Omori
Takeshi Omori
MYMasahiko Yano
Masahiko Yano
Aim: The aim of this study was to assess changes in body composition during neoadjuvant chemotherapy (NAC) and investigate whether chemotherapy-related toxicities affect body composition in patients with esophageal cancer. Patients and Methods: In ninety-four patients who underwent NAC for esophageal cancer, body composition was assessed before and after NAC. Associations between the incidence of toxicities and change in body composition during NAC were investigated. Results: Forty-four (46.8%) and 50 (53.2%) out of 94 patients were defined as having sarcopenia before and after NAC, respectively. There was no significant difference in the incidence of any toxicity pre-treatment between patients with sarcopenia and those without sarcopenia. No significant reduction in skeletal muscle mass or fat mass was observed in the patients during NAC (p=0.501 and p=0.072). However, patients who experienced grade 4 neutropenia or febrile neutropenia during NAC showed a significantly larger decrease in change of skeletal muscle mass compared to patients who did not experience those toxicities (p=0.013 and 0.036, respectively). Conclusion: The incidence of serious adverse events such as febrile neutropenia and grade 4 neutropenia is associated with a significant reduction of skeletal muscle mass during NAC. We should make an effort to reduce the incidence of adverse events in order to maintain an appropriate body composition during NAC.

1 June 2006 in Diseases of the Esophagus
Verified
Journal Article
Closed access
PDF file
MYM. Yano
M. Yano
KTK. Takachi
K. Takachi
YDY. Doki
Y. Doki
IMI. Miyashiro
I. Miyashiro
KKK. Kishi
K. Kishi
SIS. Imaoka
S. Imaoka

22 April 2010 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KTKoji Tanaka
Koji Tanaka
MYMasahiko Yano
Masahiko Yano
MMMasaaki Motoori
Masaaki Motoori
KKKentaro Kishi
Kentaro Kishi
IMIsao Miyashiro
Isao Miyashiro
OIOsamu Ishikawa
Osamu Ishikawa

1 April 2022 in Clinical Nutrition
Verified
Journal Article
Closed access
MMMasaaki Motoori
Masaaki Motoori
KSKeijiro Sugimura
Keijiro Sugimura
KTKoji Tanaka
Koji Tanaka
OSOsamu Shiraishi
Osamu Shiraishi
YKYutaka Kimura
Yutaka Kimura
MYMasahiko Yano
Masahiko Yano

1 January 2004 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TMTakuji Mori
Takuji Mori
YFYoshiyuki Fujiwara
Yoshiyuki Fujiwara
YSYurika Sugita
Yurika Sugita
TATakashi Azama
Takashi Azama
TITakaaki Ishii
Takaaki Ishii
MMMorito Monden
Morito Monden